These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18508540)

  • 21. Nucleic acids-based therapeutics in the battle against pathogenic viruses.
    Haasnoot J; Berkhout B
    Handb Exp Pharmacol; 2009; 189(189):243-63. PubMed ID: 19048203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.
    Goyenvalle A; Leumann C; Garcia L
    J Neuromuscul Dis; 2016 May; 3(2):157-167. PubMed ID: 27854216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses.
    Spurgers KB; Sharkey CM; Warfield KL; Bavari S
    Antiviral Res; 2008 Apr; 78(1):26-36. PubMed ID: 18258313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.
    Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM
    Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses.
    Lim TW; Yuan J; Liu Z; Qiu D; Sall A; Yang D
    Curr Opin Mol Ther; 2006 Apr; 8(2):104-7. PubMed ID: 16610761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
    Alvarez-Salas LM; Benítez-Hess ML; DiPaolo JA
    Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects.
    Vaillant A
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status of anti-picornavirus therapies.
    Barnard DL
    Curr Pharm Des; 2006; 12(11):1379-90. PubMed ID: 16611122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense therapeutics.
    Persidis A
    Nat Biotechnol; 1999 Apr; 17(4):403-4. PubMed ID: 10207893
    [No Abstract]   [Full Text] [Related]  

  • 31. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense DNA and RNA strategies: new approaches to therapy.
    Gibson I
    J R Coll Physicians Lond; 1994; 28(6):507-11. PubMed ID: 7884705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors.
    Wang HM; Liang PH
    Expert Opin Ther Pat; 2010 Jan; 20(1):59-71. PubMed ID: 20021285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in human picornavirus research: New findings from the AIROPico consortium.
    Wolthers KC; Susi P; Jochmans D; Koskinen J; Landt O; Sanchez N; Palm K; Neyts J; Butcher SJ
    Antiviral Res; 2019 Jan; 161():100-107. PubMed ID: 30472162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of antisense oligonucleotides in the treatment of respiratory diseases.
    Ulanova M; Schreiber AD; Befus AD
    BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
    Barata P; Sood AK; Hong DS
    Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and Opportunities for Nucleic Acid Therapeutics.
    Corey DR; Damha MJ; Manoharan M
    Nucleic Acid Ther; 2022 Feb; 32(1):8-13. PubMed ID: 34931905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of picornavirus uncoating as antiviral agents.
    Diana GD; Otto MJ; McKinlay MA
    Pharmacol Ther; 1985; 29(3):287-97. PubMed ID: 3014575
    [No Abstract]   [Full Text] [Related]  

  • 40. Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01.
    Ashizawa AT; Cortes J
    Expert Opin Drug Deliv; 2015 Jul; 12(7):1107-20. PubMed ID: 25539721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.